| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FXR |
| Uniprot No | Q96RI1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-476aa |
| 氨基酸序列 | MGSKMNLIEHSHLPTTDEFSFSENLFGVLTEQVAGPLGQNLEVEPYSQYSNVQFPQVQPQISSSSYYSNLGFYPQQPEEWYSPGIYELRRMPAETLYQGETEVAEMPVTKKPRMGASAGRIKGDELCVVCGDRASGYHYNALTCEGCKGFFRRSITKNAVYKCKNGGNCVMDMYMRRKCQECRLRKCKEMGMLAECMYTGLLTEIQCKSKRLRKNVKQHADQTVNEDSEGRDLRQVTSTTKSCREKTELTPDQQTLLHFIMDSYNKQRMPQEITNKILKEEFSAEENFLILTEMATNHVQVLVEFTKKLPGFQTLDHEDQIALLKGSAVEAMFLRSAEIFNKKLPSGHSDLLEERIRNSGISDEYITPMFSFYKSIGELKMTQEEYALLTAIVILSPDRQYIKDREAVEKLQEPLLDVLQKLCKIHQPENPQHFACLLGRLTELRTFNHHHAEMLMSWRVNDHKFTPLLCEIWDVQ |
| 预测分子量 | 70.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FXR重组蛋白的**模拟参考文献示例**(非真实文献，仅作格式参考)：
---
1. **文献名称**：*"Expression and Functional Analysis of Recombinant Farnesoid X Receptor (FXR) in Mammalian Cell Systems"*
**作者**：Chen H, et al.
**摘要**：研究报道了在哺乳动物细胞中高效表达功能性FXR重组蛋白的方法，并验证其在体外模型中调控胆汁酸靶基因(如SHP)的能力，为药物筛选提供工具。
2. **文献名称**：*"Crystal Structure of the Ligand-Binding Domain of Human FXR Recombinant Protein Complexed with Obeticholic Acid"*
**作者**：Thompson R, et al.
**摘要**：通过X射线晶体学解析了FXR重组蛋白配体结合域与药物奥贝胆酸结合的复合物结构，阐明其特异性相互作用的分子机制。
3. **文献名称**：*"Development of a Recombinant FXR Protein-Based Assay for Detecting Environmental Endocrine Disruptors"*
**作者**：Garcia M, et al.
**摘要**：利用FXR重组蛋白构建新型体外检测平台，筛选具有潜在胆汁酸代谢干扰作用的环境化合物，验证其灵敏度和特异性。
4. **文献名称**：*"Optimization of FXR Recombinant Protein Stability for High-Throughput Drug Discovery"*
**作者**：Kim S, et al.
**摘要**：通过蛋白工程改造提升FXR重组蛋白的稳定性，成功应用于大规模化合物库筛选，发现多个新型FXR激动剂/拮抗剂。
---
**备注**：以上为模拟案例，实际文献需通过PubMed、Web of Science等平台检索关键词(如“FXR recombinant protein”、“FXR expression and function”)获取。真实文献可能包括以下方向：重组表达策略、结构生物学研究、药物开发应用或代谢调控机制。
The farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, is a ligand-activated transcription factor primarily expressed in the liver, intestine, kidneys, and adipose tissue. Discovered in 1995. FXR plays a central role in regulating bile acid homeostasis, lipid metabolism, glucose balance, and inflammatory responses. It is activated by endogenous bile acids, such as chenodeoxycholic acid, which bind to its ligand-binding domain, triggering conformational changes that enable interaction with co-regulators and DNA response elements. Dysregulation of FXR signaling is linked to metabolic disorders (e.g., non-alcoholic fatty liver disease, diabetes), cholestasis, and certain cancers, making it a therapeutic target.
Recombinant FXR proteins are engineered using heterologous expression systems (e.g., E. coli, mammalian cells) to produce purified, functional FXR for research and drug development. These proteins retain key structural domains: a DNA-binding domain (DBD) for target gene recognition and a ligand-binding domain (LBD) for compound interaction. Recombinant FXR enables high-throughput screening of agonists/antagonists, structural studies (e.g., X-ray crystallography), and mechanistic investigations into receptor-ligand dynamics. Notably, obeticholic acid, an FXR agonist derived from such research, is approved for treating primary biliary cholangitis. Ongoing efforts focus on optimizing FXR modulators with tissue-specific activity and reduced side effects, underscoring the importance of recombinant FXR in advancing precision therapies for metabolic and hepatic diseases.
×
